Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
Clínica Universidad de Navarra, Madrid, Spain.
Future Oncol. 2021 Jan;17(3s):9-19. doi: 10.2217/fon-2020-1123. Epub 2020 Dec 23.
Following the failure of first-line platinum-based chemotherapy in ovarian cancer, options for further therapy in potentially platinum-responsive patients are: carboplatin doublets with pegylated liposomal doxorubicin, gemcitabine or paclitaxel in association with bevacizumab, followed by maintenance with bevacizumab (for nonpretreated patients); or maintenance monotherapy with a poly(ADP-ribose) polymerase inhibitor after a response. The choice of biological therapy depends on a patient's previous treatments and priority for a symptomatic response. In cases of a rapidly growing tumor or need for symptomatic relief, the addition of bevacizumab should be considered. Patients with limited potential sensitivity to platinum, such as those with a platinum treatment-free interval of 6-12 months, may benefit from intercalation with trabectedin and pegylated liposomal doxorubicin to possibly restore platinum sensitivity.
在卵巢癌一线铂类化疗失败后，潜在铂类反应患者的进一步治疗选择为：卡铂联合聚乙二醇脂质体阿霉素、吉西他滨或紫杉醇联合贝伐珠单抗，随后用贝伐珠单抗维持（用于未经治疗的患者）；或在有反应后用聚（ADP-核糖）聚合酶抑制剂维持单药治疗。生物治疗的选择取决于患者之前的治疗情况和对症状缓解的优先考虑。在肿瘤快速生长或需要缓解症状的情况下，应考虑添加贝伐珠单抗。对于铂类敏感性有限的患者，如铂类无治疗间隔为 6-12 个月的患者，可能受益于插入曲贝替定和聚乙二醇脂质体阿霉素，以可能恢复铂类敏感性。
